PortfoliosLab logoPortfoliosLab logo
GERN vs. VKTX
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

GERN vs. VKTX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Geron Corporation (GERN) and Viking Therapeutics, Inc. (VKTX). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, GERN achieves a -12.12% return, which is significantly higher than VKTX's -16.63% return. Over the past 10 years, GERN has underperformed VKTX with an annualized return of -8.94%, while VKTX has yielded a comparatively higher 35.08% annualized return.


GERN

1D
-0.85%
1M
-26.11%
YTD
-12.12%
6M
-8.66%
1Y
-26.11%
3Y*
-31.44%
5Y*
-3.55%
10Y*
-8.94%

VKTX

1D
0.14%
1M
-7.65%
YTD
-16.63%
6M
-17.17%
1Y
10.22%
3Y*
9.60%
5Y*
41.01%
10Y*
35.08%
*Multi-year figures are annualized to reflect compound growth (CAGR)

GERN vs. VKTX - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
GERN
Geron Corporation
-12.12%-62.71%67.77%-12.81%98.36%-23.27%16.91%36.00%-44.44%-13.04%
VKTX
Viking Therapeutics, Inc.
-16.63%-12.57%116.23%97.98%104.35%-18.29%-29.80%4.84%88.42%241.18%

Correlation

The correlation between GERN and VKTX is 0.36, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.36

Correlation (3Y)
Calculated over the trailing 3-year period

0.32

Correlation (5Y)
Calculated over the trailing 5-year period

0.37

Correlation (10Y)
Calculated over the trailing 10-year period

0.33

Correlation (All Time)
Calculated using the full available price history since Apr 30, 2015

0.30

Fundamentals

Market Cap

GERN:

$776.48M

VKTX:

$3.39B

EPS

GERN:

-$0.10

VKTX:

-$4.16

PB Ratio

GERN:

3.39

VKTX:

6.75

Total Revenue (TTM)

GERN:

$196.12M

VKTX:

$0.00

Gross Profit (TTM)

GERN:

$119.67M

VKTX:

-$208.00K

EBITDA (TTM)

GERN:

-$40.62M

VKTX:

-$501.77M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

GERN vs. VKTX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GERN
GERN Risk / Return Rank: 2020
Overall Rank
GERN Sharpe Ratio Rank: 2323
Sharpe Ratio Rank
GERN Sortino Ratio Rank: 2424
Sortino Ratio Rank
GERN Omega Ratio Rank: 2525
Omega Ratio Rank
GERN Calmar Ratio Rank: 1717
Calmar Ratio Rank
GERN Martin Ratio Rank: 1111
Martin Ratio Rank

VKTX
VKTX Risk / Return Rank: 4747
Overall Rank
VKTX Sharpe Ratio Rank: 4646
Sharpe Ratio Rank
VKTX Sortino Ratio Rank: 4747
Sortino Ratio Rank
VKTX Omega Ratio Rank: 5050
Omega Ratio Rank
VKTX Calmar Ratio Rank: 4646
Calmar Ratio Rank
VKTX Martin Ratio Rank: 4646
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GERN vs. VKTX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Geron Corporation (GERN) and Viking Therapeutics, Inc. (VKTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


GERNVKTXDifference
Sharpe ratioReturn per unit of total volatility

-0.56

Sortino ratioReturn per unit of downside risk

-0.97

Omega ratioGain probability vs. loss probability

0.97

1.11

-0.14

Calmar ratioReturn relative to maximum drawdown

-0.65

0.23

-0.87

Martin ratioReturn relative to average drawdown

-1.29

0.46

-1.75

GERN vs. VKTX - Sharpe Ratio Comparison

The current GERN Sharpe Ratio is -0.42, which is lower than the VKTX Sharpe Ratio of 0.14. The chart below compares the historical Sharpe Ratios of GERN and VKTX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


GERNVKTXDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-0.42

0.14

-0.56

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.04

0.41

-0.45

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

-0.11

0.36

-0.48

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.07

0.11

-0.18

Drawdowns

GERN vs. VKTX - Drawdown Comparison

The maximum GERN drawdown since its inception was -98.73%, which is greater than VKTX's maximum drawdown of -90.41%. Use the drawdown chart below to compare losses from any high point for GERN and VKTX.


Loading charts...

Drawdown Indicators


GERNVKTXDifference

Max Drawdown

Largest peak-to-trough decline

-98.73%

-90.41%

-8.32%

Max Drawdown (1Y)

Largest decline over 1 year

-40.51%

-45.14%

+4.63%

Max Drawdown (3Y)

Largest decline over 3 years

-78.98%

-78.86%

-0.12%

Max Drawdown (5Y)

Largest decline over 5 years

-78.98%

-78.86%

-0.12%

Max Drawdown (10Y)

Largest decline over 10 years

-86.09%

-89.26%

+3.17%

Current Drawdown

Current decline from peak

-98.34%

-68.96%

-29.38%

Average Drawdown

Average peak-to-trough decline

-86.15%

-60.01%

-26.14%

Ulcer Index

Depth and duration of drawdowns from previous peaks

20.30%

22.29%

-1.99%

Volatility

GERN vs. VKTX - Volatility Comparison

Geron Corporation (GERN) has a higher volatility of 15.09% compared to Viking Therapeutics, Inc. (VKTX) at 13.65%. This indicates that GERN's price experiences larger fluctuations and is considered to be riskier than VKTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


GERNVKTXDifference

Volatility (1M)

Calculated over the trailing 1-month period

15.09%

13.65%

+1.44%

Volatility (6M)

Calculated over the trailing 6-month period

46.90%

41.31%

+5.59%

Volatility (1Y)

Calculated over the trailing 1-year period

63.74%

73.85%

-10.11%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

82.38%

101.62%

-19.24%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

78.08%

97.09%

-19.01%

Dividends

GERN vs. VKTX - Dividend Comparison

Neither GERN nor VKTX has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

GERN vs. VKTX - Financials Comparison

This section allows you to compare key financial metrics between Geron Corporation and Viking Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0010.00M20.00M30.00M40.00M50.00M20222023202420252026
51.84M
0
(GERN) Total Revenue
(VKTX) Total Revenue
Values in USD except per share items

Frequently Asked Questions


GERN and VKTX have a correlation of 0.36, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

GERN has higher volatility (15.09%) compared to VKTX (13.65%). In terms of maximum drawdown, GERN dropped -98.73% vs VKTX's -90.41%.

VKTX currently has the higher Sharpe Ratio (0.14 vs -0.42), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for GERN and VKTX

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer